地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：18995651644
传真：17754422825
邮箱：sales@amyjet.com
Dendritics公司主要关注人类树突状细胞，希望找到能够促使CD34+造血前体细胞转化为树突状细胞（在GM-CSF和TNF-alpha存在的情况下）的细胞因子。在1992-2005年间，大量的研究使得研究者对人类树突状细胞的产生、细胞通路、C-type凝集素受体的功能及Toll-like受体的活性有了更深的理解。
DENDRITICS was started in 2005 by former members of SCHERING PLOUGH Laboratory for Immunological Research (LIR) in Dardilly, France. From their long experience at LIR, the team members of DENDRITICS have gathered complementary scientific and technological knowledge in different areas of immunology. The initial focus of LIR was in the biology of B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF) together with our colleagues of DNAX Research Institute in Palo Alto, California.
Our interest in cytokines led to the finding that human dendritic cells (DCs) could be generated in vitro from CD34+ hematopoietic progenitors cultured in the presence of GM-CSF and TNF-alpha.
The period from 1992 to 2005 saw the specialization of LIR in DC biology and was fuelled by a large-scale effort to discover and study the function of genes specifically expressed by these cells. This program led to a number of findings that contributed in particular to understanding the heterogeneity of DCs, the pathways regulating DC migration, the function of C-type lectin receptors in DCs and the activity of Toll-like receptors in DCs. Many novel genes were discovered through screening of cDNA libraries or through monoclonal antibodies raised against DCs.
<<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Dendritics"> Dendritics
艾美捷科技特约代理CovaChem公司产品。
CovaChem公司致力于为生命科学领域的科学家提供化学产品。主要涉及的领域是质谱、蛋白质组学、蛋白质科学、药物测试及药物筛选。
CovaChem is a chemical manufacturing company serving research scientists in the life sciences. We are dedicated to producing the highest quality reagents in the marketplace for use in mass spectrometry, proteomics, protein sciences, drug testing and drug development. We offer a wide range of products in both small scale and bulk quantities. For sizes larger than our catalog offering, please contact us for a custom quotation. CovaChem is proud to serve customers around the world, with their chemical, biotech, and analytical product needs. The customer is always our top priority, and this is why we offer an UNCONDITIONAL GUARANTEE for all of our products!
CovaChem的主要产品包括：
Protein Crosslinkers
LCMS & HPLC Mobile Phases
Protein Modifiers
GC Derivatization Reagents
Chemicals
MALDI Matrices
Buffers & Solvents
Beta Glucuronidase
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="CovaChem"> CovaChem
艾美捷科技特约代理Epigentek公司产品。
Epigentek公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。公司开发了700多个专利产品，为表观遗传学方面的研究和新药研发提供全面系统的解决方案。相比普通方法的产品而言，这些独特的产品在科研分析过程中更简单、更快捷、更方便、更有效。全世界的备受推崇的学者、领先的制药企业以及先进的生物技术公司都在使用Epigentek产品。让客户满意和帮助客户在试验中取得最大成功是我们进行技术创新的首要任务。
As an epigenetics company, Epigentek Group Inc. is the leading developer and provider of innovative technologies and products for epigenetic-related research. Founded in 2005, the company has since developed a comprehensive portfolio of proprietary products to provide complete and systematic solutions for epigenetics-related research and drug discovery.
Epigentek products are used all around the world by esteemed academia, leading pharmaceuticals, and cutting-edge biotechnology companies. These unique products are specifically designed to make assays much simpler, faster, more convenient, and highly more efficient than currently used methods.
产品主要有：
（1）Antibodies
DNA Methylation
Histone Modification
RNA Processing & Modification
Chromatin & Transcription
Cellular Structure & Function
Signal Transduction
Metabolism
Immunology & Inflammation
Other Primary Antibodies
Secondary AntibodiesTag Antibodies
Antibody Panel Packs
（2）Research Kits
Sample Preparation
Next Generation Sequencing
DNA Methylation
RNA Methylation
Chromatin & Transcription
Histone Methylation
Histone Acetylation
DNA Damage & Repair
Gene Editing & Silencing
（3）Proteins & Enzymes
DNA Methylation
Modified Histones
Unmodified Histones
Methylated DNA Binding
ADP Ribose
Chromatin Binding/Transcription
DNA Damage & Repair
（4）Peptides
Histone Methylation
Histone Acetylation/Deacetylation
Histone Phosphorylation
（5）Modulators & Inhibitors
DNA Methylation
Histone Acetylation
Histone Deacetylation
Histone Demethylation
Histone Phosphorylation
（7）Reagents
（8）Instruments
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Epigentek"> Epigentek
E&K Scientific公司成立于1975年，是生物技术和制药研究实验室提供实验试剂和仪器设备的主要供应商，有着超过40年的经验。
At E&K Scientific our mission is to excel in the distribution of life science research supplies by offering an unparalleled customer experience centered on technical expertise, innovation, and personalized service.
E&K offers almost 50 years of experience as a premier provider of laboratory supplies and instrumentation to the Academic, Biotech, and Pharmaceutical Research Laboratories. The company was founded in 1975 by Egon and Kay Ruf and their son, Brian Ruf, took over as President and CEO in 2000.
E&K Scientific公司的主要产品包括：
Biological Buffers
Blotting & Electrophoresis
Cell Culture
Chromatography Supplies
DNA/RNA Purification
Equipment & Instruments
Filtration & Separation
Gloves & Apparel
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="E&K Scientific"> E&K Scientific
<艾美捷科技代理Microbs品牌全系列产品
Microbs是一家处于科技前沿的创新企业，专注于微生物检测与质量控制领域的研发与服务。Microbs的核心技术——IAN®超快速微生物检测方法，是公司在微生物检测领域的重大突破。这一技术巧妙融合固相细胞术与人工智能，颠覆了传统微生物检测耗时长的局限。以往需要数天的检测流程，如今借助IAN®，仅需15分钟就能准确计数细菌、酵母菌和霉菌，极大地提高了检测效率，为微生物QC实验室的生产力提升带来了革命性变化。
具体介绍一下优势:
● IAN®全自动解决方案：操作简便，无需专业知识，即可实现定性和定量检测，并给出客观结果，无需额外解释。这一特性使得微生物检测更加普及化和便捷化，降低了检测门槛，让更多企业和机构能够轻松开展微生物检测工作。
● TVC-CAP总菌群分析产品：无需管理多个耗材，让检测流程更加简化。它适用于液体基质，能够检测总需氧和厌氧菌群，LOD（检测限）达到1个微生物/样品，具备出色的可追溯性和数据完整性，符合21 CFR第11部分的要求。
● 部门广泛：用于制造业可助优化流程、缩短交货时间、提高生产能力；在质量管控方面可以降低质量成本，实现无缺陷、无召回的目标；在实验室里，实现更快的批次发布，推动检测自动化并确保可追溯性；在供应链环节，减少库存，节省库存成本，减少安全库存和所需的存储区域。
● 全过程应用：在生物负荷测试中严控中间产品、原材料及工艺用水质量；无菌测试保障产品无菌性；环境控制全方位监测拭子、人员与空气；不合格调查能快速溯源污染，为各行业提供全流程微生物检测与质控支持。
| 产品信息 | 描述 |
| A fully automated solution | To boost productivity in your microbial QC lab, Microbs is launching IAN®, an Ultra Rapid Microbiological Method allowing an accurate enumeration of bacteria, yeast and mold within minutes, |
<艾美捷科技有限公司授权代理Katchem公司全系列产品。
产品详情请见艾美捷科技丁香通商铺或直接咨询客服人员。
https://vicbio.biomart.cn/supply/c_307368.htm
Katchem公司，位于捷克共和国Prague，是一家主要生产硼化学产品的公司，其产品主要包括：硼酸盐和碳硼酸盐簇、十硼烷（14）簇、碳硼烷、COSANes、金属硼氢化物、硼砂及其衍生物、硼烷-路易斯碱配合物、硼酸和酯、BNCT用化合物、非硼化合物、二氨基甲酸盐和催化系统等。
【产品应用场景1】
中子治疗，硼中子俘获治疗（Boron Neutron Capture Therapy，简称BNCT）。
BNCT的原理是利用发生在肿瘤细胞内的核反应摧毁癌细胞，由于同时需要中子源和B，因此，是一种二元化治疗肿瘤的新方法。BNCT的基本过程分为两部分：首先在肿瘤细胞内聚积足够量的稳定性核素B，即将一种含B的化合物引入患者体内，这种化合物与肿瘤细胞有很强的亲和力，进入体内后，迅速聚集于肿瘤细胞内，而在其它正常组织中分布很少；然后再用中子束照射肿瘤部位，使中子与肿瘤细胞内聚集的B发生B（n,α）Li核反应，B俘获中子后，形成同位素B，B迅速分裂为重粒子Li和α，肿瘤细胞被α射线和Li照射而死亡。适用于硼中子捕获治疗的含硼化合物应具备四个重要特性：对人体毒性低、对正常细胞的亲和性低、对癌细胞的亲和性高（最好可达正常细胞的3倍以上，且每克癌细胞分布的硼达到20微克以上）、能被人体迅速从正常细胞和血液移除。目前仅有两种含硼化合物应用在临床试验：Sodium Borocaptate (BSH)以及Boronophenylalanine(BPA)。
【产品应用场景2】
电池研发。
【热销产品】
【产品列表】
| 产品编码 | 产品名称 | CAS号 | 规格（g） |
| 410 | Sodium triborate dioxane | CAS [33220-35-8] | 1、5、10、25、50 |
| 458 | Cesium triborate | CAS [12007-45-3] | 1、5、10 |
| 564 | LIthium triborate dioxane | CAS [212697-88-6] | 1、5、10 |
| 315 | Triethylammonium decahydrodecaborate | CAS [12075-73-9] | 5、10、25、50、100 |
| 333 | Tetramethylammonium decahydrodecaborate | CAS [12073-87-9] | 5、10、25、50、100 |
| 493 | Sodium decahydrodecaborate | CAS [12294-20-1] | 5、10、25、50、100 |
| 459 | Ammonium decahydrodecaborate | CAS [12008-61-6] | 5、10、25、50、100 |
| 229 | Potassium decahydrodecaborate | CAS [12447-89-1] | 5、10、25、50、100 |
| 246 | Cesium decahydrodecaborate | CAS [12008-58-1] | 10、25、50、100 |
| 675 | Lithium decahydrodecaborate, trihydrate | CAS [64719-89-7 anhyd] | 5、10、25 |
| 812 | Calcium decahydrodecaborate, trihydrate | CAS [64719-84-2 anhyd] | 5、10、25 |
| 804 | Cesium decachlorodecaborate | CAS [12360-16-6] | 5、10、25、50 |
| 805 | Cesium decabromodecaborate | CAS [12356-10-4] | 5、10、25、50 |
| 803 | Cesium decaiododecaborate | CAS [88423-95-4] | 5、10、25、50 |
| 324 | Cesium tetradecahydroundecaborate | CAS [12008-72-9] | 5、10、25、50、100 |
| 453 | Triethylammonium tetradecahydroundecaborate | CAS [12106-44-4] | 5、10、25、50、100 |
| 614 | Potassium tetradecahydroundecaborate | CAS [52261-21-9] | 5、10、25、50、100 |
| 615 | Sodium tetradecahydroundecaborate | CAS [52261-23-1] | 5、10、25、50、100 |
| 372 | Trimethylammonium tetradecahydroundecaborate | CAS [12076-74-3] | 5、10、25、50、100 |
| 684 | Lithium tetradecahydroundecaborate, trihydrate | CAS [52261-22-0 anhyd.] | 1、5、10 |
| 815 | Calcium tetradecahydroundecaborate, dihydrate | 1、5、10 | |
| 290 | Triethylammonium dodecahydrododecaborate | CAS [12551-42-7] | 5、10、25、50、100、250、1000 |
| 316 | Cesium dodecahydrododecaborate | CAS [12008-75-2] | 5、10、25、50、100、250、1000 |
| 228 | Potassium dodecahydrododecaborate | CAS [12008-77-4] | 5、10、25、50、100、250、1000 |
| 257 | Sodium dodecahydrododecaborate | CAS [12008-78-5] | 5、10、25、50、100、250、1000 |
| 328 | Sodium dodecahydrododecaborate anhydrous, <0.1% water | CAS [12008-78-5] | 5、10、25、50、100、250 |
| 569 | Lithium dodecahydrododecaborate, tetrahydrate | CAS [1166383-94-3] | 5、10、25、50、100、250、1000 |
| 445 | Magnesium dodecahydrododecaborate, tetrahydrate | CAS [53572-04-6 anhyd.] | 5、10、25 |
| 446 | Cobalt dodecahydrododecaborate, dihydrate | ||
| 597 | Calcium dodecahydrododecaborate monohydrate | CAS [90157-87-2 anhyd.] | 5、10、25 |
| 492 | Rubidium dodecahydrododecaborate | CAS [12598-46-8] | 5、10、25 |
| 243 | Sodium dodecachlorododecaborate | CAS [111637-82-2] | 5、10、25、100 |
| 244 | Sodium dodecabromododecaborate | CAS [1253735-09-9] | 5、10、25、100 |
| 550 | Sodium dodecaiodododecaborate | CAS [149211-37-0] | 5、10、25、100 |
| 544 | Sodium hydroxydodecaborate | CAS [56189-13-0] | 1、5、10 |
| 347 | Cesium dodecahydroxydodecaborate | CAS [12589-26-3] | 1、5、10、50 |
| 211 | Sodium mercaptododecaborate, N-BSH | CAS [144885-51-8] | 1、5、10、25、50 |
| 266 | Cesium mercaptododecaborate, N-BSH | CAS [12448-23-6] | 1、5、10、25、50 |
| 587 | Tetramethylammonium mercaptododecaborate, N-BSH | CAS [135274-62-3] | 1、5、10、25、50 |
| 489 | syn -Octadecaborane(22) | CAS No. [21107-45-9] | 1、5、10 |
| 488 | anti -Octadecaborane(22) | CAS No. [21107-56-2] | 1、5、10 |
| 359 | Mixture of syn - and anti -octadecaboranes(22) | 1、5、10、20 | |
| 414 | Triethylammonium decahydrodecaborate 10B | ||
| 556 | Sodium decahydrodecaborate 10B, GB-10 | CAS [12373-10-3] | 1、5、10、25 |
| 258 | Triethylammonium dodecahydrododecaborate 10B | 1、10、25、50 | |
| 226 | Sodium dodecahydrododecaborate 10B | CAS [109851-98-1] | 1、10、25、50 |
| 588 | Cesium dodecahydrododecaborate 10B | CAS [109788-95-6] | 1、10、25、50 |
| 500 | Lithium dodecahydrododecaborate 10B, tetrahydrate | CAS [51745-90-5 anhyd.] | 1、10、25、50 |
| 210 | Sodium mercaptododecaborate 10B, BSH | CAS [12448-24-7] | 1、5、10、50 |
| 603 | Tetramethylammonium mercaptododecaborate 10B | CAS [130207-66-8] | 1、5、10、50 |
| 401 | Cesium mercaptododecaborate 10B | CAS [109742-44-1] | 1、5、10、50 |
| 486 | Triethylammonium dodecahydrododecaborate 11B | 1、10、25、50 | |
| 491 | Sodium dodecahydrododecaborate 11B | 1、5、10 | |
| 466 | Cesium dodecahydrododecaborate 11B | CAS [1347742-49-7] | 1、5、10 |
| 485 | Rubidium dodecahydrododecaborate 11B | CAS [1347742-48-6] | 1、2、5、10 |
| 450 | Sodium mercaptododecaborate 11B | CAS [459142-76-8] | 1、5、10 |
| 457 | Cesium carbaundecaborate | CAS [51391-30-1] | 1、5、10、25、50、100、250 |
| 456 | 7-Amino-7-carbaundecaborate | CAS [12373-10-3] | 1、5、10、25、50、100 |
| 264 | 7-Trimethylamino-7-carbaundecaborate | CAS [31117-16-5] | 1、5、10、25、50、100、250 |
| 676 | Sodium carbaundecaborate | CAS [68084-95-7] | 1、5、10 |
| 677 | Lithium carbaundecaborate, hemihydrate | CAS [2169943-32-0] | 1、5、10 |
| 251 | 1-Amino-1-carbadodecaborate | CAS [749831-19-4] | 1、5 |
| 252 | 1-Trimethylamine-1-carbadodecaborane | CAS [92468-34-3] | 1、5 |
| 212 | Trimethylammonium carbadodecaborate | CAS No.[108608-25-9] | 1、5、10、20、50 |
| 213 | Cesium carbadodecaborate | CAS No.[12539-26-3] | 1、5、10、20、50 |
| 421 | Triethylammonium carbadodecaborate | CAS No.[223548-06-9] | 1、5、10、20、50 |
| 242 | Potassium carbadodecaborate | CAS No.[92468-39-8] | 1、5、10、20、50 |
| 647 | Sodium carbadodecaborate | CAS No.[92468-38-7] | 1、5、10、20、50 |
| 648 | Lithium carbadodecaborate hemihydrate | CAS No.[92468-37-6 anhyd.] | 1、5、10、20、50 |
| 813 | Calcium carbadodecaborate trihydrate | CAS No.[2077150-90-2 anhyd.] | 1、5、10、20、50 |
| 523 | Cesium 1-methyl-1-carbadodecaborate new | CAS No.[176099-40-4] | 1、5、10 |
| 349 | Trimethylammonium 1-propyl-1-carbadodecaborate new | 1、5、10 | |
| 351 | Trimethylammonium 1-mercapto-1-carbadodecaborate new | 1、5、10 | |
| 365 | Trimethylammonium 1-hydroxy-1-carbadodecaborate new | CAS No.[2077207-91-9] | 1、5、10 |
| 366 | Trimethylammonium 1-carboxy-1-carbadodecaborate new | CAS No.[1252604-78-6] | 1、5、10 |
| 378 | Cesium closo -1-carbadecaborate | CAS No.[12539-20-7] | 1、5、10 |
| 649 | Sodium closo -1-carbadecaborate | CAS No.[94322-26-6] | 1、5、10 |
| 650 | Lithium closo -1-carbadecaborate, hydrate | CAS No.[94322-25-5 anhyd.] | 1、5、10 |
| 814 | Calcium closo -1-carbadecaborate, dihydrate | 1、5、10 | |
| 412 | Trimethylammonium 7,8-dicarbaundecaborate | CAS No.[12543-22-5] | 1、5、10、25、50、100 |
| 613 | Cesium 7,8-dicarbaundecaborate | CAS No.[63748-65-2] | 1、5、10、25、50、100 |
| 673 | Sodium 7,8-dicarbaundecaborate | CAS No.[12602-34-5] | 1、5、10、25、50、100 |
| 682 | Lithium 7,8-dicarbaundecaborate dihydrate | CAS No.[1629094-87-6 anhyd.] | 1、5、10、25、50、100 |
| 214 | Trimethylammonium 7-methyl-7,8-dicarbaundecaborate | 1、5、10、25、50 | |
| 495 | Trimethylammonium 7,9-dicarbaundecaborate | CAS No.[54531-56-5] | 1、5、10、25、50、100 |
| 384 | Cesium 7,9-dicarbaundecaborate | CAS No.[12305-33-8] | 1、5、10、25、50、100 |
| 674 | Sodium 7,9-dicarbaundecaborate | 1、5、10、25、50、100 | |
| 683 | Lithium 7,9-dicarbaundecaborate trihydrate | CAS No.[1629094-86-5 anhyd.] | 1、5、10、25、50、100 |
| 208 | Decaborane(14) | CAS [17702-41-9] | 1、5、10、25、50、100、250 |
| 419 | Bis(acetonitrile)-decabora | CAS [28377-97-1] | 5、20、100、250 |
| 238 | Bis(dimethylsulfide)-decaborane | CAS [28377-92-6] | 5、20、100、250 |
| 204 | Decaborane(14) 10B(Isotopic enrichment: 10B >99.5%) | CAS [488806-75-3] | 1、5、10、25 |
| 301 | Decaborane(14) 11B(Isotopic enrichment: 11B >99.8%) | CAS [94601-45-3] | 1、5、10、25 |
| 199 | o -Carborane | CAS No. [16872-09-6] | 1、5、10、25、50、100、250、500 |
| 209 | 1-Methyl-o -carborane | CAS No. [16872-10-9] | 5、10、25、50、100 |
| 233 | 1-Bromomethyl-o -carborane | CAS No. [19496-84-5] | 5、10、25、50、100 |
| 269 | 1,2-Dimethyl-o -carborane | CAS No. [17032-21-2] | 1、5、10 |
| 332 | 1-n-Propyl-o -carborane | CAS No. [23940-16-1] | 1、5、10 |
| 463 | 1-Hexyl-o -carborane | CAS No. [20740-05-0] | 1、5、10、25、50、100 |
| 464 | 1,2-Dihexyl-o -carborane | CAS No. [280762-92-7] | 1、5、10、25、50 |
| 203 | 1-Phenyl-o -carborane | CAS No. [16390-61-7] | 1、5、10、25、50、100 |
| 465 | 1,2-Didodecyl-o -carboran | CAS No. [943026-62-8] | 1、5、10、25、50 |
| 609 | 1-Methyl-2-propargyl-o -carborane | CAS No. [23868-57-7] | 1、2、5 |
| 318 | 1-Hydroxymetyl-o -carborane | CAS No. [19610-34-5] | 1、5、10 |
| 448 | 1,2-Bis(hydroxymethyl)-o -carborane | CAS No. [19610-37-8] | 1、5、10 |
| 297 | o -Carborane-1-carboxylic acid | CAS No. [18178-04-6] | 1、5、10 |
| 253 | o -Carborane-1,2-dicarboxylic acid | CAS No. [23835-80-5] | 1、5、10 |
| 480 | 1-Trimethylsilyl-o -carborane | CAS No. [18971-67-0] | 1、5、10、25 |
| 516 | 1-Hydroxy-o -carborane | CAS No. [23987-99-7] | 1、2、5、10 |
| 502 | 1,2-Dihydroxy-o -carboran | CAS No. [868382-62-1] | 1、2、5、10 |
| 293 | 1-Mercapto-o -carborane | CAS No. [17526-07-7] | 1、5、10、25 |
| 232 | 1,2-Dimercapto-o -carbora | CAS No. [23810-63-1] | 1、5、10、25 |
| 345 | 9-Iodo-o -carborane | CAS No. [17830-03-4] | 5、10、20 |
| 346 | 9,12-Diiodo-o -carborane | CAS No. [17702-35-1] | 5、10、20 |
| 240 | 9-Mercapto-o -carborane | CAS No. [64493-43-2] | 1、5、10 |
| 433 | 9,12-Dimercapto-o -carborane | CAS No. [75572-47-3] | 1、2、5 |
| 440 | 8,9,12-Trimercapto-o -carborane | CAS No. [1423066-18-5] | 1、2、5 |
| 200 | m -Carborane | CAS No. [16986-24-6] | 1、5、10、25、50、100、250 |
| 518 | 1-Methyl-m -carborane | CAS No. [17378-55-1] | 1、5、10、25 |
| 317 | 1-Allyl-7-methyl-m -carbor | CAS No. [20670-09-1] | 1、5、10、25 |
| 319 | 1,7-Diallyl-m -carborane | CAS No. [1232168-57-8] | 1、5、10、25 |
| 320 | 1,7-Bis(hydroxymethyl)-m -carborane | CAS No. [23924-78-9] | 1、5、10、50 |
| 298 | m -Carborane-1-carboxylic acid | CAS No. [18581-81-2] | 1、5、10 |
| 261 | 1,7-Bis(chlordimethylsilyl)-m -carborane | CAS No. [16996-48-8] | 1、5、10、50、100、250 |
| 259 | 1,7-Bis(methoxydimethylsilyl)-m -carborane | CAS No. [17631-41-3] | 1、5、10、50、100、250 |
| 321 | 1,7-Bis(hydroxydimethylsilyl)-m -carborane | CAS No. [22742-19-4] | 1、5、10、50、100、250 |
| 481 | 1-Vinyldimethylsilyl-m -carborane | 1、5、10、25 | |
| 501 | 1,7-Bis(vinyltetramethyldisiloxy)-m -carborane | CAS No. [210707-88-3] | 1、5、10、25、50 |
| 527 | 1-Hydroxy-m -carborane | CAS No. [23988-02-5] | 1、5、10 |
| 532 | 1,7-Dihydroxy-m -carbora | CAS No. [55629-26-0] | 1、5、10 |
| 496 | 1-Mercapto-m -carborane | CAS No. [56310-80-6] | 1、2、5、10 |
| 434 | 1,7-Dimercapto-m -carborane | CAS No. [23810-64-2] | 1、2、5、10 |
| 513 | 9-Mercapto-m -carborane | CAS No. [64493-44-3] | 1、2、5、10 |
| 201 | p -Carborane | CAS No. [20644-12-6] | 1、5、10、25、50 |
| 267 | p -Carborane-1,12-dicarboxylic acid | CAS No. [23087-99-2] | 1、5、10 |
| 528 | 1-Hydroxy-p -carborane | CAS No. [54360-43-9] | 1、5、10 |
| 533 | 1,12-Dihydroxy-p -carbora | CAS No. [55629-27-1] | 1、5、10 |
| 497 | 1-Mercapto-p -carborane | CAS No. [69985-41-7] | 1、2、5、10 |
| 498 | 1,12-Dimercapto-p -carborane | CAS No. [24228-77-1] | 1、2、5、10 |
| 341 | 4,5-Dicarba-arachno -nonaborane(13) new | CAS No. [113678-30-1] | 5、10、25 |
| 339 | 4,6-Dicarba-arachno -nonaborane(13) new | CAS No. [17653-38-2] | 5、10、25 |
| 340 | 6,9-Dicarba-arachno -decaborane(14) new | 5、10、25 | |
| 227 | 5,6-Dicarba-nido -decaborane(12) | CAS No. [41655-26-9] | 5、10、20 |
| 539 | Ten-vertex-o -carborane | CAS No. [41655-27-0] | 2、5 |
| 354 | Ten-vertex-m -carborane | CAS No. [23704-81-6] | 2、5 |
| 255 | Ten-vertex-p -carborane | CAS No. [23653-12-6] | 2、5 |
| 206 | o -Carborane 10B | CAS No. [760207-79-2] | 1、5、10 |
| 207 | 1-Methyl-o -carborane 10B | CAS No. [1177403-84-7] | 1、5、10 |
| 205 | m -Carborane 10B | 1、5、10 | |
| 595 | o -Carborane 11B | CAS No. [1291083-31-2] | 1、5、10 |
| 407 | m -Carborane 11B | CAS No. [1291083-36-7] | 1、5、10 |
| 271 | COSAN | CAS No.[60146-18-1] | 1、5、10、25、50、100、250 |
| 218 | Chloro-protected cesium bis(1,2-dicarbollide)-cobaltate | CAS No.[84913-29-1] | 1、5、10、25、50、100、250 |
| 393 | Bromo-protected cesium bis(1,2-dicarbollide)-cobaltate | CAS No.[84933-24-4] | 1、5、10、50 |
| 292 | COSAN dioxanate | CAS No.[188478-29-7] | 1、2、5、10、50 |
| 476 | NISAN | CAS No.[36548-55-7] | 1、5、10、25、50 |
| 483 | FESAN | CAS No.[12304-97-1] | 1、5、10、25、50 |
| 520 | Lithium COSAN | CAS No.[167568-99-2] | 1、5 |
| 517 | Sodium COSAN | CAS No.[99492-72-5] | 1、5 |
| 392 | Sodium borohydride | CAS [16940-66-2] | 50、100、250、500、1000 |
| 429 | Rubidium borohydride | CAS [20346-99-0] | 1、2、5、10 |
| 225 | Cesium borohydride | CAS [19193-36-3] | 1、2、5、10 |
| 596 | Calcium borohydride | CAS [17068-95-0] | 1、5、10、25 |
| 636 | Magnesium borohydride | CAS [16903-37-0] | 1、5、10、25 |
| 263 | Lithium borodeuteride | CAS [15246-28-3] | 1、2、5、10 |
| 361 | Lithium borohydride 10B | 1、2、5、10 | |
| 362 | Lithium borodeuteride 10B | 1、2、5、10 | |
| 323 | Lithium borohydride 11B | 1、2、5、10 | |
| 239 | Lithium borodeuteride 11B | CAS [1242073-72-8] | 1、2、5、10 |
| 363 | Lithium borohydride 7Li | 1、2、5、10 | |
| 367 | Lithium borodeuteride 7Li | 1、2、5、10 | |
| 370 | Lithium borohydride 7Li, 10B | CAS [139980-21-5] | 1、2、5、10 |
| 371 | Lithium borodeuteride 7Li, 10B | CAS [163779-14-4] | 1、2、5、10 |
| 442 | Lithium borohydride 7Li, 11B | CAS [139980-20-4] | 2、5 |
| 499 | Lithium borodeuteride 7Li,11B | CAS [163779-13-3] | 1、2、5、10 |
| 326 | Sodium borodeuteride | CAS [15681-89-7] | 5、10 |
| 202 | Sodium borohyride 10B | CAS [72901-47-4] | 1、2、5、10 |
| 373 | Sodium borodeuteride 10B | CAS [163779-18-8] | 1、2、5、10 |
| 396 | Sodium borohyride 11B | CAS [72901-46-3] | 1、2、5、10 |
| 397 | Sodium borodeuteride 11B | CAS [163779-17-7] | 1、2、5、10 |
| 379 | Potassium borodeuteride | CAS [17440-13-0] | 5、10 |
| 455 | Potassium borohyride 10B | 1、2、5、10 | |
| 417 | Potassium borodeuteride 10B | 1、2、5、10 | |
| 447 | Potassium borohyride 11B | CAS [1417734-35-0] | 1、2、5、10 |
| 413 | Potassium borodeuteride 11B | 1、2、5、10 | |
| 508 | Calcium borodeuteride | CAS [122042-59-5] | 1、2、5、10 |
| 352 | Calcium borohydride 10B | 1、2、5、10 | |
| 355 | Calcium borohydride 11B | 1、2、5、10 | |
| 220 | Calcium borodeuteride 11B | CAS [1309461-44-6] | 1、2、5、10 |
| 656 | Magnesium borohydride 11B | 1、2、5、10 | |
| 452 | Cesium borohydride 11B | CAS [1417734-38-3] | 1、2、5、10 |
| 504 | Cesium borodeuteride 11B | 1、2、5、10 | |
| 462 | Rubidium borohydride 11B | CAS [1417734-37-2] | 1、2、5、10 |
| 505 | Rubidium borodeuteride 11B | CAS [1445366-23-3] | 1、2、5、10 |
| 300 | Dimethylamine borane complex, DMAB | CAS [74-94-2] | 10、25、100、250、1000 |
| 415 | Ammonia borane complex | CAS [13774-81-7] | 10、20、50、100 |
| 415,1 | Ammonia borane complex +90% (purity >90%) | CAS [13774-81-7] | 10、20、50、100、200、500、1000 |
| 294 | Triethylamine borane complex | CAS [1722-26-5] | 10、50、100、500 |
| 221 | Dimethylsulfide borane complex, 10M solution in Me2S (d=0.8g/ml 26°C) | CAS [13292-87-0] | 100、800 |
| 375 | Ammonia borane complex 10B | CAS [77074-21-6] | 1、5、10 |
| 468 | Ammonia borane complex 11B | CAS [77069-36-4] | 1、5、10 |
| 563 | Deuteroammonia deuteroborane complex 11B | CAS [933675-78-6] | 1、2、5 |
| 577 | Deuteroammonia deuteroborane complex | CAS [20214-17-9] | 1、2、5 |
| 435 | Triethylamine deuteroborane complex | CAS [4680-65-3] | 10、25、50、100 |
| 311 | Triethylamine borane complex 10B | CAS [115959-96-1] | 10、25、50、100 |
| 449 | Triethylamine deuteroborane complex 10B | 10、25、50、100 | |
| 430 | Triethylamine borane complex 11B | 10、25、50、100 | |
| 411 | Triethylamine deuteroborane complex 11B | 10、25、50、100 | |
| 477 | Dimethylsulfide deuteroborane complex (purity > 95%) | CAS [117981-99-4] | 10、25、50、100 |
| 254 | Dimethylsulfide borane complex 10B(purity > 95%) | 10、25、50、100 | |
| 471 | Dimethylsulfide deuteroborane complex 10B(purity > 95%) | 10、25、50、100 | |
| 594 | Dimethylsulfide borane complex 11B(purity > 95%) | 10、25、50、100 | |
| 473 | Dimethylsulfide deuteroborane complex 11B(purity > 95%) | CAS [2230877-77-5] | 10、25、50、100 |
| 219 | 4-Borono-L-phenylalanine, L-BPA | CAS [76410-58-7] | 1、5、10、50 |
| 541 | Trimethylborate | CAS [121-43-7] | 5、10、50、100、400、800 |
| 268 | 4-Borono-L-phenylalanine 10B, BPA (also provide BPA produced by GMP.) | CAS [80994-59-8] | 1、10、50 |
| 436 | Trimethylborate 10B | CAS [4832-27-3] | 5、10、50、100、400、800 |
| 262 | Tri-n-butylborate 10B | CAS [207742-80-1] | 10、50、100、400、800 |
| 344 | Triphenylborate 10B | 10、50、100、400 | |
| 409 | Trimethylborate 11B | CAS [3349-42-6] | 3、10、25、50 |
| 423 | Tri-n-butylborate 11B | CAS [207742-78-7] | 10、25、50、100 |
| 431 | Triphenylborate 11B | 10、25、50、100 | |
| 210 | Sodium mercaptododecaborate 10B, BSH | CAS [12448-24-7] | 1、5、10、50 |
| 268 | 4-Borono-L-phenylalanine 10B, BPA ( also provide BPA produced by GMP.) | CAS [80994-59-8] | 1、10、50 |
| 556 | Sodium decahydrodecaborate 10B, GB-10 | CAS [666747-96-2] | 1、5、10、25 |
| 230 | TODGA | CAS [342794-43-8] | 5、10、20、50、100 |
| 296 | DIHOCA dihexyloctanoyl amide | CAS [75397-93-2] | 5、10、20、50、100 |
| 611 | TEHDGA | CAS [669087-46-1] | 5、10、20、50、100 |
| 348 | 7Li-Lithium bromide | CAS [34007-72-2] | 5、10、20、50、100 |
| 553 | 7Li-Lithium iodide | CAS [29911-74-8] | 5、10、20 |
| 308 | 7Li-Lithium chloride | CAS [20233-17-4] | 5、10、20 |
更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技授权代理Katchem全系列硼化学产品"> 艾美捷科技授权代理Katchem全系列硼化学产品
艾美捷科技特约代理Cloud-Clone公司产品。
Cloud-Clone Corp公司，现有4000种Elisa试剂盒、15000种抗体、7000种蛋白，涵盖人、小鼠、大鼠、牛、猪、兔、鸡、豚鼠、犬、猴、羊、鱼、植物等物种，涉及细胞因子、信号转导、免疫、代谢、内分泌、消化、神经、生殖、肿瘤、激酶、CD/粘附分子等19个领域。
Cloud-Clone Corp. (CCC, Wuhan) is located in Export Processing Zone. Its quality management system is certified with ISO 9001:2008 and ISO 13485:2003. The featured products are reagents for life science research. 75% of the customers come from USA and Europe. Based on profound accumulation of technology and huge resource of primers, cDNAs, plasmids, hybridoma cells, as well as semi-products of detection reagent, CCC can provide 11,000 proteins, 19,000 antibodies and 7,000 immunoassay kits with short lead time. The Protein Center has four production platforms, including polypeptide synthesis platform, small-molecule modification platform, natural protein extraction platform, recombinant protein expression and purification platform using prokaryotic (E.coli) and eukaryotic (yeast, baculovirus or mammalian cells) expression systems. The Antibody Center has established a high-throughput technology platform for monoclonal, polyclonal and cloudclonal antibody production. The Preparation Center focuses on assay kit development and production. At present, its main products include ELISA kits and CLIA kits. The Detection Center is responsible for quality control of all the products, including proteins, antibodies and assay kits. All Cloud-Clone products are inspected by a three-level quality control system, including raw-material QC, semi-finished product QC, and end-product QC.
Cloud-Clone公司的主要产品包括：
AssayKits
Monoclonal antibodies
Polyclonal antibodies
proteins
Cells/CS Extracts/ES Mediums/MS Disease models/DS
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技特约代理Cloud-Clone公司产品"> 艾美捷科技特约代理Cloud-Clone公司产品
艾美捷科技特约代理Biogems产品。
BioGems意为生物钻石，其产品涵盖多种荧光标记的流式抗体、具有生物活性的功能性抗体，以及流式细胞术辅助试剂，如溶血剂和破膜剂等。BioGems产品全部在美国生产，目前已拥有超过500种流式试剂和600余种重组蛋白产品。
Through the establishment of joint collaborations with reputable manufacturers of top-quality life-science research products such as PeproTech Inc., BioGems has positioned itself to become a highly competitive source for a wide-range of recombinant protein and flow-cytometry reagents. Currently, our catalog contains more than 600 recombinant proteins and over 500 flow cytometry reagents. To keep up with the rapidly advancing research fronts, BioGems continuously adds new products to its catalog. All of our products are subjected to a thorough and rigorous quality and performance testing to ensure that each and every product meets the highest established standards. Providing our customers with the highest-quality products at affordable prices is our goal. We are confident that the unique business arrangements of BioGems together with our highly skilled and experienced personnel will enable us to achieve this goal.
主要产品分类：
（1）Flow Cytometry
Conjugated Antibodies
SAFIRE Functional Antibodies
Isotype Controls
Custom and Bulk Reagents
Purified Antibodies
Buffers and Solutions
（2）Recombinant Proteins
Growth Factors & Cytokines
Animal-Free Cytokines
Chemokines
Neurotrophins
Other Proteins
Anti Cytokine & Chemokine Antibodies
（3）Small Molecules
Receptor Antagonist and Inhibitors
Receptor Agonists and Activators
（4）Pre-Coated Elisa Kits
Human
Mouse
Rat
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="BioGems"> BioGems
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年，提供近200种亚磷酰胺和核苷酸合成用固相交联单体，以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.
Berry & Associates的主要产品包括：
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
美国Plant Cell Technology公司为商业及研究用植物组织培养实验室和植物种植者开发、生产了旗舰产品PPM™ (Plant Preservative Mixture)，它是一种广谱抗微生物剂，可以杀死细菌和真菌细胞，防止真菌孢子的萌发，并在较高浓度下能消除内源性污染的外植体。研究表明PPM™活性成分可以渗透过真菌或细菌细胞壁，抑制柠檬酸循环和电子传递链等中心代谢循环中的关键酶的活性，并且可以抑制培养基中的单糖和氨基酸向真菌和细菌细胞的运输。PPM™能有效地抑制植物细胞和植物组织培养中的通过空气、水、人传播的微生物污染及内源性污染，而不会影响体外种子发芽、愈伤组织增殖和愈伤组织的再生。并且，PPM™具有热稳定性，可以和培养基一起灭菌，同时比常用抗生素价更低廉，可以作为植物组织培养基的标准成分。
The principal PCT scientist involved in the development of the PPM™ application is Dr. Assaf Guri. Dr. Assaf Guri holds degrees in genetics, applied genetics and plant breeding from the Hebrew University in Jerusalem and Michigan State University in the US. Before joining Plant Cell Technology, Inc., Dr. Guri worked with the Volcani Agricultural Research Center in Israel, Michigan State University in East Lansing, Michigan and DNAP in New Jersey.
<更多详情请联系
艾美捷科技有限公司
全国服务热线：400-6800-868
邮箱：sales@amyjet.com
网站：www.amyjet.com
地址：武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话：15172431432
传真：18372041646
邮箱：sales@amyjet.com
0.3963
